Skip to content
MARKETS / BALCAO / NTRR
BALCAO · MEDICINAL CHEMICALS & BOTANICAL PRODUCTS · SMALL CAP

Neutra Corp. NTRR

12 fiscal years on record · USD · FY2022 reported · SEC filings only
$67,996
▼ 26.1% YoY
$-561,417
In brief

What this company does

Along with participating in the actual nutraceutical products, we plan to research and bring new technology to the nutraceutical space. One of the nutraceutical sub-markets is the new thriving medical cannabis market, in which we intend to participate. We intend to entrust the manufacturing to a nutraceutical contractor to private label all of our products and to sell them under our unique brand. On January 23, 2018, we entered into an agreement with Artillery Labs to sell and market natural nutraceuticals online.

Written from the business description in Neutra Corp.'s annual report to the U.S. Securities and Exchange Commission, filed 2 August 2024. Every sentence was checked against that document before publication.

Growth
USD 67,996.00
Revenue, FY2022 · full 12-year series below
Revenue $ Net income $
FY2022 · Revenue 67996.0 · Net income -561417.0
40000.080000.0-250000.0-500000.02011201320152017201920212022
Compound annual growth
+119.9%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−826 cents
lost on every revenue dollar
Operating margin Net margin
FY2022 · Operating -437.8% · Net -825.7%
-5000%-10000%2011201320152017201920212022
ROE

Not applicable: equity was negative in this period, so return on equity has no meaning.

Gross margin51.9%
Operating margin-437.8%
Net margin-825.7%
Return on assets-544.8%
EBITDAUSD -218,769.00

Cash & shareholders
returned in FY2022 · dividends + net buybacks
Free cash flow $
FY2021 · FCF -445842.0
-250000.0-500000.02011201320152017201920212022

Total assetsUSD 75,175.00
EquityUSD -773,820.00
CashUSD 1,969.00
Current ratio0.03×

Equity funds -1029% of total assets.

The 12-year record
12 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 202220212020201920182017201620152014201320122011
Revenue $B0.00.00.00.0········
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0·········
Income tax $B0.0·0.00.0········
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B·−0.0−0.0·········
EPS, diluted $··0.000.00−0.16−0.10−0.41−1.25−3.36−0.13−0.16−0.15
Dividend / sh $············
Payout %············
ROE %············
Shares out B2.741.781.490.620.030.010.000.000.000.010.000.00

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 47 reconciliationsAUDITED

Reconciled in 12 of 19 fiscal years. 48 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityMedicinal Chemicals & Botanical Products
Listed onOTC market
Incorporated inWyoming
Fiscal year endsJanuary 31
SEC categorysmaller reporting company
Data on record since2011

Share this section

Download image